Side-by-side · Research reference
ChonlutenvsTesamorelin
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-MechanisticHUMAN-REVIEWED8/38 cited
BFDA-ApprovedFlagship27/68 cited
Chonluten
Khavinson Bioregulator · Bronchial Mucosa
Oral · Sublingual · Per Protocol
Tesamorelin
GHRH Analogue · FDA-Approved
SQ · Abdomen · Once Daily
01Mechanism of Action
Parameter
Chonluten
Tesamorelin
Primary target
Bronchial epithelial cells and respiratory mucosa tissue complexes
Hypothalamic GHRH receptorsEGRIFTA® (tesamorelin for inje 2010
Pathway
Bioregulatory peptide interaction → modulation of proliferative and inflammatory pathways in monocyte/macrophage populationsAvolio 2022
GHRH → Pituitary GH release → Liver IGF-1 synthesisFalutz 2007
Downstream effect
Regulation of proliferative activity and inflammatory mediator production in respiratory-associated immune cellsAvolio 2022
Increased GH pulsatility, elevated IGF-1, lipolysis of visceral adipose tissueFalutz 2010
Feedback intact?
—
Yes — physiological pulsatility preserved
Origin
Khavinson bioregulator peptide complex derived from bronchial mucosa tissue extract methodology
Synthetic 44-AA GHRH analogue with trans-3-hexenoic-acid modification for stabilityEGRIFTA® (tesamorelin for inje 2010
02Dosage Protocols
Parameter
Chonluten
Tesamorelin
Typical protocol dose
10–20 mg / day
Russian bioregulator tradition dosing; not standardized in Western literature.
—
Frequency
Once or twice daily
Once daily (morning or pre-sleep)
Aligns with natural GH pulse.
Route
Oral (capsule) or sublingual
Sublingual claimed for enhanced bioavailability; not validated.
—
Duration
10–30 days per cycle
Traditional Khavinson protocol; cyclic administration common.
12–52 weeks
VAT returns within months of stopping.
Clinical validation
None (PubMed indexed)
—
Reconstitution
—
Sterile water per labeling
Preserved at 2–8 °C after reconstitution.
Timing
—
Empty stomach, pre-sleep preferred
03Metabolic / Fat Loss Evidence
Parameter
Chonluten
Tesamorelin
Primary fat target
—
Visceral adipose tissue (VAT) — abdominal
Effect on lean mass
—
Modest lean mass preservation / slight increase
Effect reversibility
—
VAT returns within months of stopping
Key publication
—
Falutz et al. NEJM 2007 · Falutz JCEM 2010 · FDA approval 2010Falutz 2007Falutz 2010EGRIFTA® (tesamorelin for inje 2010
04Side Effects & Safety
Parameter
Chonluten
Tesamorelin
Documented adverse events
No published safety data in PubMed-indexed literature
—
Theoretical risks
Peptide hypersensitivity, GI intolerance (uncharacterized)
—
Drug interactions
Unknown — no pharmacokinetic studies available
—
Pregnancy / lactation
No data — avoid
—
Injection site reaction
—
Erythema, pruritus, redness (common)
Fluid retention / Edema
—
Peripheral edema, arthralgia, carpal tunnel (GH-axis effect)
IGF-1 elevation
—
Dose-dependent; supraphysiological levels = discontinue
Cancer risk
—
Contraindicated in active malignancy (GH/IGF-1 axis); theoretical tumour growth riskEGRIFTA® (tesamorelin for inje 2010
Antibody formation
—
~50% at 26 weeks; non-neutralising in most; rare hypersensitivity (<1%)Sévigny 2018
GI symptoms
—
Nausea, diarrhea (mild, transient)
Absolute Contraindications
Chonluten
- ·Known hypersensitivity to peptide components
Tesamorelin
- ·Active malignancy or history of treated cancer
- ·Pregnancy
- ·Hypersensitivity to tesamorelin or mannitol
- ·Disruption of hypothalamic-pituitary axis (trauma, tumour, radiation)
Relative Contraindications
Chonluten
- ·Pregnancy and lactation (insufficient data)
- ·Active malignancy (theoretical bioregulator concern)
Tesamorelin
- ·Untreated diabetes (monitor HbA1c)
- ·Severe carpal tunnel syndrome
- ·Acute critical illness
05Administration Protocol
Parameter
Chonluten
Tesamorelin
1. Preparation
Typically supplied as capsules or sublingual tablets. No reconstitution required. Store in cool, dry place away from light.
Add 2.1 mL sterile water to 2 mg lyophilised vial. Roll gently — do not shake. Solution should be clear.
2. Oral route
Swallow capsule with water, 20–30 minutes before meals or as directed. Traditional Khavinson protocol emphasizes empty stomach for absorption.
Subcutaneous — abdomen preferred. Rotate sites (avoid same spot within 2 cm). Avoid navel and waistband area.
3. Sublingual route
Place tablet under tongue, allow dissolution for 1–2 minutes. Avoid swallowing immediately. Claimed to bypass first-pass metabolism.
Once daily. Preferred: evening, 2–3 hrs post-meal, before sleep — aligns with natural GH secretion pulse.
4. Timing
Morning dose preferred; may split into twice-daily if higher dose used. Consistency emphasized in bioregulator protocols.
Lyophilised: room temp, light-protected. Reconstituted: refrigerate 2–8 °C, use within 21 days.
5. Cycle protocol
10–30 day cycles common in Russian tradition. Rest period of 1–3 months between cycles often recommended, though no published evidence for this approach.
27–31G, 4–8 mm insulin syringe. Pinch skin, 45° angle for lean individuals.
06Stack Synergy
Chonluten
— no documented stacks
Tesamorelin
+ Ipamorelin
StrongTesamorelin (GHRH analogue) and ipamorelin (GHRP / ghrelin mimetic) act on two distinct receptor systems to amplify GH release synergistically — GHRH receptor + ghrelin receptor. This dual-axis stimulation produces a more robust, sustained GH pulse than either alone while maintaining physiological pulsatility. Ipamorelin is highly selective with minimal cortisol or prolactin elevation, making it the preferred GHRP pairing.
- Tesamorelin
- 2 mg SQ · evening
- Ipamorelin
- 200–300 mcg SQ · same injection
- Frequency
- Once daily, pre-sleep
- Primary benefit
- Maximal GH pulsatility, fat loss, recovery, sleep quality